142
Views
19
CrossRef citations to date
0
Altmetric
Review

Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer

, &
Pages 3305-3322 | Published online: 05 Oct 2016

References

  • National Cancer Institute [webpage on the Internet]SEER Stat Fact Sheets: Bladder Cancer2016 Available from: http://seer.cancer.gov/statfacts/html/urinb.htmlAccessed February 4, 2016
  • American Cancer SocietyCancer Facts & FiguresAtlanta, GAAmerican Cancer Society2016
  • SiegelRMaJZouZJemalACancer statistics, 2014CA Cancer J Clin201464192924399786
  • Weill Cornell Medical College [webpage on the Internet]Types of Bladder Cancers2015 Available from: https://www.cornellurology.com/clinical-conditions/bladder-cancer/types-of-bladder-cancers/Accessed August 10, 2015
  • Cancer Research UK [webpage on the Internet]Types of Bladder Cancer2015 Available from: http://www.cancerresearchuk.org/about-cancer/type/bladder-cancer/about/types-of-bladder-cancerAccessed August 12, 2015
  • KaufmanDSShipleyWUFeldmanASBladder cancerLancet2009374968523924919520422
  • KantorAFHartgePHooverRNFraumeniJFEpidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladderCancer Res19884813385338553378221
  • LottSLopez-BeltranAMontironiRMacLennanGTChengLSoft tissue tumors of the urinary bladder: part II: malignant neoplasmsHum Pathol200738796397717574946
  • KirkaliZChanTManoharanMBladder cancer: epidemiology, staging and grading, and diagnosisUrology2005666 suppl 143416399414
  • ReidLMLeavIKwanPWRussellPMerkFBCharacterization of a human, sex steroid-responsive transitional cell carcinoma maintained as a tumor line (R198) in athymic nude miceCancer Res19844410456045736467211
  • MallinKDavidKACarrollPRMilowskyMINanusDMTransitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007)J Urol201118551631163621419456
  • YeeDSIshillNMLowranceWTHerrHWElkinEBEthnic differences in bladder cancer survivalUrology201178354454921782222
  • CalleEERodriguezCWalker-ThurmondKThunMJOverweight, obesity, and mortality from cancer in a prospectively studied cohort of US adultsNew Engl J Med2003348171625163812711737
  • QinQXuXWangXZhengXYObesity and risk of bladder cancer: a meta-analysis of cohort studiesAsian Pac J Cancer Prev20131453117312123803089
  • WyszynskiATanyosSAReesJRBody mass and smoking are modifiable risk factors for recurrent bladder cancerCancer2014120340841424122218
  • VillanuevaCMFernandezFMalatsNGrimaltJOKogevinasMMeta-analysis of studies on individual consumption of chlorinated drinking water and bladder cancerJ Epidemiol Community Health200357316617312594192
  • FerrísJBerbelOAlonso-LópezJGarciaJOrtegaJAEnvironmental non-occupational risk factors associated with bladder cancerActas Urol Esp201337957958623618510
  • MinkPJAlexanderDDBarrajLMKelshMATsujiJSLow-level arsenic exposure in drinking water and bladder cancer: a review and meta-analysisRegul Toxicol Pharmacol200852329931018783726
  • ChuHACrawford-BrownDJInorganic arsenic in drinking water and bladder cancer: a meta-analysis for dose-response assessmentInt J Environ Res Public Health20063431632217159272
  • BurgerMCattoJWDalbagniGEpidemiology and risk factors of urothelial bladder cancerEur Urol201363223424122877502
  • FreedmanNDSilvermanDTHollenbeckARSchatzkinAAbnetCCAssociation between smoking and risk of bladder cancer among men and womenJAMA2011306773774521846855
  • ChenCHShunCTHuangKHStopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancerBJU Int2007100228128617419696
  • SathiakumarNMacLennanPAMandelJDelzellEA review of epidemiologic studies of triazine herbicides and cancerCrit Rev Toxicol201141S1134
  • GaertnerRRTheriaultGPRisk of bladder cancer in foundry workers: a meta-analysisOccup Environ Med2002591065566312356924
  • KoutrosSKaragasMFriesenM0118 lifetime occupational exposure to diesel exhaust and bladder cancer among men in New EnglandOccup Environ Med201471suppl 1A75
  • TravisLBCurtisREGlimeliusBBladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphomaJ Natl Cancer Inst19958775245307707439
  • FletcherOEastonDAndersonKGilhamCJayMPetoJLifetime risks of common cancers among retinoblastoma survivorsJ Natl Cancer Inst200496535736314996857
  • PavanelloSMastrangeloGPlacidiDCYP1A2 polymorphisms, occupational and environmental exposures and risk of bladder cancerEur J Epidemiol201025749150020559687
  • NauwelaërsGBellamriMFessardVTureskyRJLangouëtSDNA adducts of the tobacco carcinogens 2-amino-9 H-pyrido [2, 3-b] indole and 4-aminobiphenyl are formed at environmental exposure levels and persist in human hepatocytesChem Res Toxicol20132691367137723898916
  • Bladder Cancer Diagnosis [webpage on the Internet]Bladder Cancer2015 Available from: http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-diagnosisAccessed August 10, 2015
  • TilkiDBurgerMDalbagniGUrine markers for detection and surveillance of non-muscle-invasive bladder cancerEur Urol201160348449221684071
  • FradetYGrossmanHBGomellaLA comparison of hexamineolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter studyJ Urol20071781687317499291
  • KaraogluIvan der HeijdenAGWitjesJAThe role of urine markers, white light cystoscopy and fluorescence cystoscopy in recurrence, progression and follow-up of non-muscle invasive bladder cancerWorld J Urol201432365165924166285
  • GrossmanHBGomellaLFradetYA phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancerJ Urol20071781626717499283
  • KarlATritschlerSStanislausPPositive urine cytology but negative white-light cystoscopy: an indication for fluorescence cystoscopy?BJU Int2009103448448718793301
  • KimTGriffinJGHolzbeierleinJMSextonWJImaging in localized and advanced bladder cancerManagement of Bladder CancerNew York CitySpringer20155971
  • de BoerEHarlaarNJTaruttisAOptical innovations in surgeryBr J Surg20151022e56e7225627136
  • UddinMJMarnettLJSynthesis of 5- and 6-carboxy-X-rhodaminesOrg Lett200810214799480118837556
  • CekanovaMUddinMJBartgesJWMolecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivoCancer Prev Res (Phila)20136546647623531445
  • UddinMJCrewsBCBlobaumALSelective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agentsCancer Res20107093618362720430759
  • American Cancer Society [webpage on the Internet]How Is Bladder Cancer Found?2015 Available from: http://www.cancer.org/cancer/bladdercancer/overviewguide/bladder-cancer-overview-diagnosedAccessed August 28, 2015
  • BlickCGNazirSAMallettSEvaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinicBJU Int20121101849422122739
  • HafeezSHuddartRAdvances in bladder cancer imagingBMC Med201311110423574966
  • TekesAKamelIImamKDynamic MRI of bladder cancer: evaluation of staging accuracyAm J Roentgenol2005184112112715615961
  • NicolauCBuneschLPeriLAccuracy of contrast-enhanced ultrasound in the detection of bladder cancerBr J Radiol20118410081091109921123306
  • SunMTrinhQDDiagnosis and staging of bladder cancerHematol Oncol Clin North Am2015292205218vii25836929
  • American Cancer Society [webpage on the Internet]Bladder Cancer Staging2014 Available from: http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-stagingAccessed August 7, 2015
  • RouprêtMBabjukMCompératEEuropean guidelines on upper tract urothelial carcinomas: 2013 updateEur Urol20136361059107123540953
  • KhannaCLindblad-TohKVailDThe dog as a cancer modelNat Biotechnol200624910651066
  • Mayo Clinic [webpage on the Internet]Diseases and Conditions: Bladder Cancer2014 Available from: http://www.mayoclinic.org/diseases-conditions/bladder-cancer/basics/risk-factors/con-20027606Accessed August 12, 2014
  • SolsonaEIborraIRicosJVMonrosJLCasanovaJDumontREffectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followupJ Urol199916141120112310081851
  • Ali-el-DeinBNabeehAel-BazMShamaaSAshamallahASingle-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled studyBr J Urol19977957317359158511
  • LammDLBlumensteinBACrawfordEDA randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladderN Engl J Med199132517120512091922207
  • HerrHWSchwalbDMZhangZFIntravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trialJ Clin Oncol1995136140414087751885
  • KawaiKMiyazakiJJorakuANishiyamaHAkazaHBacillus Calmette–Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccineCancer Sci20131041222723181987
  • LammDLBCG in perspective: advances in the treatment of superficial bladder cancerEur Urol199527suppl 1287750528
  • Chemotherapy for Bladder Cancer [webpage on the Internet]Treatment for Bladder Cancer2015 Available from: http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-treating-chemotherapyAccessed 12 August, 2015
  • KanataniANakagawaTKawaiTAdjuvant chemotherapy is possibly beneficial for locally advanced or node-positive bladder cancerClin Genitourin Cancer2014132e107e11225456839
  • CarballidoEMRosenbergJEOptimal treatment for metastatic bladder cancerCurr Oncol Rep201416940425056737
  • DraganYPSargentLXuYDXuYHPitotHCThe initiation-promotion-progression model of rat hepatocarcinogenesisExp Biol Med199320211624
  • HenningsHGlickABGreenhalghDACritical aspects of initiation, promotion, and progression in multistage epidermal carcinogenesisExp Biol Med1993202118
  • SmithGCareyFABeattieJMutations in APC, Kirstenras, and p53 – alternative genetic pathways to colorectal cancerProc Natl Acad Sci U S A200299149433943812093899
  • McCulloughSHuYLiRBRCA1 in initiation, invasion, and metastasis of breast cancer: a perspective from the tumor microenvironmentManselRFodstadOJiangWMetastasis of Breast Cancer11NetherlandsSpringer20073146
  • McConkeyDJLeeSChoiWMolecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progressionUrol Oncol201028442944020610280
  • NetworkTCComprehensive molecular characterization of urothelial bladder carcinomaNature2014507749231532224476821
  • MitraAPDatarRHCoteRJMolecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identificationJ Clin Oncol200624355552556417158541
  • SherrCJMcCormickFThe RB and p53 pathways in cancerCancer Cell20022210311212204530
  • AprelikovaOXiongYLiuETBoth p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinaseJ Biol Chem19952703118195181977629134
  • HollsteinMSidranskyDVogelsteinBHarrisCCp53 mutations in human cancersScience1991253501549531905840
  • EsrigDElmajianDGroshenSAccumulation of nuclear p53 and tumor progression in bladder cancerN Engl J Med199433119125912647935683
  • CooperMJHaluschakJJJohnsonDp53 mutations in bladder carcinoma cell linesOncol Res19946125695797787250
  • ZhuHBYangKXieYQLinYWMaoQQXieLPSilencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cellsWorld J Surg Oncol2013112223356234
  • ChatterjeeSJDatarRYoussefzadehDCombined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinomaJ Clin Oncol20042261007101314981105
  • El-DeiryWSTokinoTVelculescuVEWAF1, a potential mediator of p53 tumor suppressionCell19937548178258242752
  • AhmadISansomOJLeungHYExploring molecular genetics of bladder cancer: lessons learned from mouse modelsDis Model Mech20125332333222422829
  • HinataNShirakawaTZhangZRadiation induces p53-dependent cell apoptosis in bladder cancer cells with wild-type- p53 but not in p53-mutated bladder cancer cellsUrol Res200331638739612955365
  • PavletichNPChambersKAPaboCOThe DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spotsGenes Dev1993712B255625648276238
  • HarmsKLChenXThe functional domains in p53 family proteins exhibit both common and distinct propertiesCell Death Differ200613689089716543939
  • TeufelDPFreundSMBycroftMFershtARFour domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53Proc Natl Acad Sci U S A2007104177009701417438265
  • MizuaraiSYamanakaKKotaniHMutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cellsCancer Res200666126319632616778209
  • PiantinoCBReisSTVianaNIPrima-1 induces apoptosis in bladder cancer cell lines by activating p53Clinics (Sao Paulo)20136829730323644847
  • WangSKonorevEAKotamrajuSJosephJKalivendiSKalyanaramanBDoxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms: intermediacy of H2O2- and p53-dependent pathwaysJ Biol Chem200427924255352554315054096
  • ZhuXBelmontHJPrice-SchiaviSVisualization of p53264–272/HLA-A* 0201 complexes naturally presented on tumor cell surface by a multimeric soluble single-chain T cell receptorJ Immunol200617653223323216493083
  • FishmanMNThompsonJAPennockGKPhase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264–272)/HLA-A* 0201 complex, in patients with advanced malignanciesClin Cancer Res201117247765777521994418
  • StadlerWMLernerSPGroshenSPhase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 statusJ Clin Oncol201129253443344921810677
  • HanahanDWeinberg RobertAHallmarks of cancer: the next generationCell2011144564667421376230
  • van RhijnBWvan der KwastTHVisANFGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinomaCancer Res20046461911191415026322
  • JebarAHHurstCDTomlinsonDCJohnstonCTaylorCFKnowlesMAFGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinomaOncogene200524335218522515897885
  • SunCHChangYHPanCCActivation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladderHistopathology20115871054106321707707
  • van RhijnBWLurkinIRadvanyiFKirkelsWJvan der KwastTHZwarthoffECThe fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rateCancer Res20016141265126811245416
  • MansourAAbdulreheemMElsherbeenyMEGFR expression predicts recurrence in patients undergoing adjuvant chemotherapy for advanced bladder cancerCancer Res20147419 suppl904
  • ZhaoJXuWZhangZPrognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysisInt Urol Nephrol2015471879425384433
  • KopparapuPKBoorjianSARobinsonBDExpression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancerAnticancer Res20133362381239023749886
  • TsaiYCYehCHTzenKYTargeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinomaEur J Cancer20134961458146623153706
  • EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200737096052103211118156031
  • KnowlesMAPlattFMRossRLHurstCDPhosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancerCancer Metastasis Rev2009283–430531620013032
  • CantleyLCNeelBGNew insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathwayProc Natl Acad Sci U S A19999684240424510200246
  • Puzio-KuterAMCastillo-MartinMKinkadeCWInactivation of p53 and Pten promotes invasive bladder cancerGenes Dev200923667568019261747
  • CarayolNVakanaESassanoACritical roles for mTORC2-and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cellsProc Natl Acad Sci U S A201010728124691247420616057
  • ZengZSarbassovDDSamudioIJRapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AMLBlood200710983509351217179228
  • StreeterEHHarrisALAngiogenesis in bladder cancer – prognostic marker and target for future therapySurg Oncol2002111–28510012031871
  • JonesAFujiyamaCBlancheCRelation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1 alpha and hypoxia-inducible factor-2 alpha in human bladder tumors and cell linesClin Cancer Res2001751263127211350893
  • De LucaACarotenutoARachiglioAThe role of the EGFR signaling in tumor microenvironmentJ Cell Physiol2008214355956717894407
  • GravasSBosinakouIKehayasPGiannopoulosAUrinary basic fibroblast growth factor in bladder cancer patients. Histopathological correlation and clinical potentialUrol Int200473217317715331904
  • StachowiakMKMoffettJJoyAPuchaczEFlorkiewiczRStachowiakEKRegulation of bFGF gene expression and subcellular distribution of bFGF protein in adrenal medullary cellsJ Cell Biol199412712032237929563
  • LiADubeySVarneyMLDaveBJSinghRKIL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesisJ Immunol200317063369337612626597
  • ZhuZShenZXuCInflammatory pathways as promising targets to increase chemotherapy response in bladder cancerMediators Inflamm2012201252869022811589
  • LammDLBacillus Calmette-Guerin immunotherapy for bladder cancerJ Urol1985134140473892050
  • ThompsonRHDongHLohseCMPD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinomaClin Cancer Res20071361757176117363529
  • NajjarYGKirkwoodJMPembrolizumab: pharmacology and therapeutics reviewHematologic20151719
  • LutzkyJAntoniaSJBlake-HaskinsAA phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumorsPaper presented at: ASCO Annual Meeting Proceedings2014
  • ChoDCSosmanJASznolMClinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC)J Clin Oncol201331a4505
  • PeggsKSQuezadaSAKormanAJAllisonJPPrinciples and use of anti-CTLA4 antibody in human cancer immunotherapyCurr Opin Immunol200618220621316464564
  • RibasAKeffordRMarshallMAPhase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaJ Clin Oncol201331561662223295794
  • HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
  • PrietoPAYangJCSherryRMCTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanomaClin Cancer Res20121872039204722271879
  • YangJCHughesMKammulaUIpilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitisJ Immunother200730882518049334
  • WongHCJengEKRhodePRThe IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8+ T cells into innate-like effector cells with antitumor activityOncoimmunology2013211e2644224404427
  • ToselloA-CMaryFAmiotMBernardAMaryDActivation of T cells via CD55: recruitment of early components of the CD3-TCR pathway is required for IL-2 secretionJ Inflamm19974811327
  • CioccaDRCalderwoodSKHeat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implicationsCell Stress Chaperones20051028616038406
  • SchmittEGehrmannMBrunetMMulthoffGGarridoCIntracellular and extracellular functions of heat shock proteins: repercussions in cancer therapyJ Leukoc Biol2007811152716931602
  • da Rocha DiasSFriedlosFLightYSpringerCWorkmanPMaraisRActivated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycinCancer Res20056523106861069116322212
  • O’Callaghan-SunolCGabaiVLShermanMYHsp27 modulates p53 signaling and suppresses cellular senescenceCancer Res20076724117791178818089808
  • ProiaDASangJHeSSynergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer modelsInvest New Drugs20123062201220922227828
  • YingWDuZSunLGanetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapyMol Cancer Ther201211247548422144665
  • KamadaMSoAMuramakiMRocchiPBeraldiEGleaveMHsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cellsMol Cancer Ther20076129930817218637
  • MaruyamaRToyookaSToyookaKOAberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological featuresCancer Res200161248659866311751381
  • BertinoEMOttersonGARomidepsin: a novel histone deacetylase inhibitor for cancerExpert Opin Investig Drugs201120811511158
  • SuzukiTTanakaRHamadaSNakagawaHMiyataNDesign, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitorsBioorg Med Chem Lett20102031124112720056538
  • LiDRZhangHPeekESynergy of histone-deacetylase inhibitor AR-42 with cisplatin in bladder cancerJ Urol2015194254755525748177
  • ChenXScapaJLiuDGodbeyWCancer-specific promoters for expression-targeted gene therapy: ran, brms1, and mcm5J Gene Med20161878910127140445
  • KalluriRNeilsonEGEpithelial-mesenchymal transition and its implications for fibrosisJ Clin Invest2003112121776178414679171
  • MaschlerSWirlGSpringHTumor cell invasiveness correlates with changes in integrin expression and localizationOncogene200524122032204115688013
  • ZhuJPanXZhangZGaoJZhangLChenJDownregulation of integrin-linked kinase inhibits epithelial-to-mesenchymal transition and metastasis in bladder cancer cellsCell Signal20122461323133222570869
  • SachsMDRauenKARamamurthyMIntegrin α v and coxsackie adenovirus receptor expression in clinical bladder cancerUrology200260353153612350512
  • TsujiSChenXHancockBPreclinical evaluation of VAX-IP, a novel bacterial minicell-based biopharmaceutical for nonmuscle invasive bladder cancerMol Ther Oncolytics201631600427119118
  • WangHCaiZYangFEnhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F/RGD on bladder cancerUrology2014832508.e13508.e19
  • van der HorstGBosLvan der MarkMTargeting of alpha-V integrins reduces malignancy of bladder carcinomaPLoS One201499e10846425247809
  • MitsuzukaKHandaKSatohMAraiYHakomoriSA specific microdomain (“glycosynapse 3”) controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of α3β1 integrin with CD9J Biol Chem200528042355453555316103120
  • LiCYangZDuYBCMab1, a monoclonal antibody against aberrantly glycosylated integrin α3β1, has potent antitumor activity of bladder cancer in vivoClin Cancer Res201420154001401325002124
  • MohammedSIKnappDWBostwickDGExpression of cycloox-ygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladderCancer Res199959225647565010582676
  • RathoreKAlexanderMCekanovaMPiroxicam inhibits Masitinib-induced cyclooxygenase 2 expression in oral squamous cell carcinoma cells in vitroTransl Res2014164215816824631063
  • ThananRMurataMMaNNuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancerMediators Inflamm2012201216587922577245
  • YuZPestellTGLisantiMPPestellRGCancer stem cellsInt J Biochem Cell Biol201244122144215122981632
  • ChanKSEspinosaIChaoMIdentification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cellsProc Natl Acad Sci U S A200910633140161402119666525
  • MarottaLLAlmendroVMarusykAThe JAK2/STAT3 signaling pathway is required for growth of CD44+ CD24–stem cell–like breast cancer cells in human tumorsJ Clin Invest20111217272321633165
  • DamrauerJSHoadleyKAChismDDIntrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biologyProc Natl Acad Sci U S A201411183110311524520177
  • LiYRogoffHAKeatesSSuppression of cancer relapse and metastasis by inhibiting cancer stemnessProc Natl Acad Sci U S A201511261839184425605917
  • KurtovaAVXiaoJMoQBlocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistanceNature2015517753320921325470039
  • SonpavdeGJonesBSBellmuntJChoueiriTKSternbergCNFuture directions and targeted therapies in bladder cancerHematol Oncol Clin North Am2015292361376x25836940
  • DingJXuDPanCCurrent animal models of bladder cancer: awareness of translatability (review)Exp Ther Med20148369169925120584
  • ErtürkECohenSPriceJBryanGTPathogenesis, histology, and transplantability of urinary bladder carcinomas induced in albino rats by oral administration of N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamideCancer Res19692912221922285387262
  • BecciPJThompsonHJStrumJMBrownCCSpornMBMoonRCN-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder cancer in C57BL/6× DBA/2 F1 mice as a useful model for study of chemoprevention of cancer with retinoidsCancer Res19814139279327459879
  • OliveiraPPalmeiraCLourençoLLopezCEvaluation of DNA content in preneoplastic changes of mouse urinary bladder induced by N-butyl-N-(4-hydroxybutyl) nitrosamineJ Exp Clin Cancer Res200524460916471324
  • LuYLiuPWenWCross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent modelsAm J Transl Res20103182721139803
  • OyasuREpithelial tumours of the lower urinary tract in humans and rodentsFood Chem Toxicol19953397477557557748
  • ZhangZTPakJHuangHYRole of Ha-ras activation in superficial papillary pathway of urothelial tumor formationOncogene200120161973198011360181
  • HeFMoLZhengXYDeficiency of pRb family proteins and p53 in invasive urothelial tumorigenesisCancer Res200969249413942119951992
  • ChengJHuangHZhangZTOverexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growthCancer Res200262144157416312124355
  • ZhangNLiDShaoJWangXAnimal models for bladder cancer: the model establishment and evaluation (Review)Oncol Lett2015941515151925788992
  • TeicherBATumor models for efficacy determinationMol Cancer Ther20065102435244317041086
  • EklundLBryMAlitaloKMouse models for studying angiogenesis and lymphangiogenesis in cancerMol Oncol20137225928223522958
  • BibbyMOrthotopic models of cancer for preclinical drug evaluation: advantages and disadvantagesEur J Cancer200440685285715120041
  • LodillinskyCRodriguezVVauthayLSandesECasabéAEijánAMNovel invasive orthotopic bladder cancer model with high cathepsin B activity resembling human bladder cancerJ Urol2009182274975519539312
  • CekanovaMRathoreKAnimal models and therapeutic molecular targets of cancer: utility and limitationsDrug Des Devel Ther2014819111921
  • MakIWEvaniewNGhertMLost in translation: animal models and clinical trials in cancer treatmentAm J Transl Res20146211424489990
  • NorrisAMLaingEJValliVECanine bladder and urethral tumors: a retrospective study of 115 cases (1980–1985)J Vet Intern Med1992631451531619591
  • MutsaersAJWidmerWRKnappDWCanine transitional cell carcinomaJ Vet Intern Med200317213614412683611
  • GlickmanLTSchoferFSMcKeeLJReifJSGoldschmidtMHEpidemiologic study of insecticide exposures, obesity, and risk of bladder cancer in household dogsJ Toxicol Environ Health19892844074142593174
  • WellerRWolfAOyejideATransitional cell carcinoma of the bladder associated with cyclophosphamide therapy in a dogJ Amer Anim Hosp Assoc19795733736
  • BryanJNKeelerMRHenryCJBryanMEHahnAWCaldwellCWA population study of neutering status as a risk factor for canine prostate cancerProstate200767111174118117516571
  • WithrowSJVailDMPageRWithrow and MacEwen’s Small Animal Clinical OncologyElsevier Health Sciences2013
  • KnappDWGlickmanNWDeNicolaDBBonneyPLLinTLGlickmanLTNaturally-occurring canine transitional cell carcinoma of the urinary bladder A relevant model of human invasive bladder cancerPaper presented at: Urologic Oncology Seminars and Original Investigations2000
  • OkajimaEHiramatsuTHiraoKUrinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in dogsCancer Res1981415195819667214364
  • PatronekGJWatersDJGlickmanLTComparative longevity of pet dogs and humans: implications for gerontology researchJ Gerontol A1997523B171B178
  • HerrHShipleyWBajorinDCancer of the bladderCancer: Principles and Practice of Oncology6th edPhiladelphia, PALippincott Williams & Wilkins200113961418
  • KnappDWRamos-VaraJAMooreGEDhawanDBonneyPLYoungKEUrinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug developmentILAR J201455110011824936033
  • DillALEberlinLSCostaABMultivariate statistical identification of human bladder carcinomas using ambient ionization imaging mass spectrometryChem-A Eur J2011171028972902
  • CekanovaMUddinMJBartgesJWMolecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivoCancer Prev Res201365466476
  • BurgerMCattoJWDalbagniGEpidemiology and risk factors of urothelial bladder cancerEur Urol201363223424122877502
  • MeutenDTumors of the urinary systemMeutenDTumors in Domestic Animals4th edHoboken, NJJohn Wiley & Sons Inc2002509546
  • OwenLNTNM Classification of Tumours in Domestic AnimalsGenevaWorld Health Organization1980
  • WalkerMBreiderMIntraoperative radiotherapy of canine bladder cancerVeter Radiol1987286200204
  • KnappDWRichardsonRCBottomsGDTeclawRChanTCPhase I trial of piroxicam in 62 dogs bearing naturally occurring tumorsCancer Chemother Pharmacol19922932142181733554
  • KnappDWGlickmanNWWidmerWRCisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancerCancer Chemother Pharmacol200046322122611021739
  • KnappDSchmidtBWidmerWPreliminary results of carboplatin/piroxicam therapy in canine transitional cell carcinomaPaper presented at: Proceedings 17th Veterinary Cancer Society – American College of Veterinary Radiology Conference1997Chicago, IL
  • DhawanDCraigBAChengLEffects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladderMol Cancer Ther2010951371137720423998
  • LowPSHenneWADoorneweerdDDDiscovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseasesAcc Chem Res200841112012917655275
  • DhawanDRamos-VaraJANaughtonJFTargeting folate receptors to treat invasive urinary bladder cancerCancer Res201373287588423204225
  • HahnNMBonneyPLDhawanDSubcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug developmentJ Urol2012187130230922099988
  • LienKGeorgsdottirSSivanathanLChanKEmmeneggerULow-dose metronomic chemotherapy: a systematic literature analysisEur J Cancer201349163387339523880474
  • SchremppDRChildressMOStewartJCMetronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinomaJ Am Vet Med Assoc2013242111534153823683018
  • CekanovaMUddinMJLegendreAMSingle-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine modelJ Biomed Opt2012171111600211600223117797
  • RathoreKCekanovaMAnimal model of naturally occurring bladder cancer: characterization of four new canine transitional cell carcinoma cell linesBMC Cancer201414146524964787
  • DhawanDRamos-VaraJAStewartJCZhengRKnappDWCanine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancerUrol Oncol200927328429218562222
  • RamlauRGorbunovaVCiuleanuTEAflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non–small-cell lung cancer: a randomized, controlled phase III trialJ Clin Oncol201230293640364722965962
  • YakesFMChenJTanJCabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growthMol Cancer Ther201110122298230821926191
  • SleijferSRay-CoquardIPapaiZPazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC study 62043)J Clin Oncol200927193126313219451427
  • JordanVCTamoxifen as the first successful targeted therapy in cancer: the gift that kept on givingBreast Cancer Management201434321326
  • WenPYYungWMellinghoffIKPhase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastomaPaper presented at: ASCO Annual Meeting ProceedingsChicago, IL, USA2014
  • AngevinEGrunwaldVRavaudAA phase II study of dovitinib (TKI258), an FGFR-and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC)Paper presented at: ASCO Meet Abstr2011
  • BendellJCPapadopoulosKJonesSFAbstract B243: a phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumorsMol Cancer Ther20111011 supplB243B243
  • NordstromJLGorlatovSZhangWAnti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcg receptor binding propertiesBreast Cancer Res201113R12322129105
  • DaviesBThomasonAEllstonR457 Preclinical pharmacology of AZD5312, a generation 2.5 antisense oligonucletotide targeting the androgen receptor with differentiated activity from enzalutamideEur J Cancer20145015024103146
  • KirchnerGIMeier-WiedenbachIMannsMPClinical pharmacokinetics of everolimusClin Pharmacokinet2004432839514748618
  • HidalgoMRowinskyEKThe rapamycin-sensitive signal transduction pathway as a target for cancer therapyOncogene200019566680668611426655
  • DesaiND’CruzOTrieuVCombination regimens of nabrapamycin (ABI-009) effective against MDA-MB-231 breast-tumor xenograftsCancer Res2009913
  • Paper presented at the thirty-Second Annual CTRC-AACR San Antonio Breast Cancer SymposiumDec 10–13, 2009San Antonio, TXCancer Research20096924Supplement
  • SteinbergGDShoreNKarshLA Phase I/II study of vesigenurtacel-l (hs-410) or placebo in combination with Bacillus Calmette-Guérin (BCG) in patients with non-muscle invasive bladder cancer (NMIBC)J ImmunoTherapy Cancer20142suppl 381
  • XuWJonesMLiuBEfficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myelomaCancer Res201373103075308623644531
  • RibasAHansonDCNoeDATremelimumab (CP-675,206), a cytotoxic T lymphocyte–associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancerOncologist200712787388317673618
  • YangPColemanJLiYSLITRK6, the target of a novel antibody drug conjugate AGS15E, is expressed in bladder and other cancersPaper presented at: CANCER RESEARCH2013
  • KozłowskaAMackiewiczJMackiewiczATherapeutic gene modified cell based cancer vaccinesGene2013525220020723566846
  • BoniVRixeORascoDAbstract A73: a phase I first-inhuman (FIH) study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs)(NCT01156870)Mol Cancer Ther20131211 supplA73A73
  • FerrajoliALeeBNSchletteEJLenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemiaBlood2008111115291529718334676
  • GoelSMitaACMitaMA phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignanciesClin Cancer Res200915124207421219509177
  • MieleESpinelliGPMieleETomaoFTomaoSAlbumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancerInt J Nanomedicine200949919516888
  • RocheMKyriakouHSeidenMDrug evaluation: tesetaxel – an oral semisynthetic taxane derivativeCurr Opin Invest Drugs200671210921099
  • LattanzioRGhasemiRBrancatiFMembranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancerOncogenesis201439e11825178039
  • HanadaMMizunoSFukushimaASaitoYNoguchiTYamaokaTA new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complexCancer Sci1998891112291238
  • HudsonELesterJFGemcitabine and carboplatin in the treatment of transitional cell carcinoma of the urothelium: a single centre experience and review of the literatureEur J Cancer Care2010193324328
  • LanglebenASupkoJGHotteSAbstract LB-171: a phase 1 dose escalation study of BBI608, a first-in-class cancer stem cell pathway inhibitor in patients with advanced malignanciesCancer Res2010708 supplLB171
  • IsakoffSOvermoyerBTungNA phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancerJ Clin Oncol20102818S1019